Irulya Therapeutics (IRLA) closed at $31.00 on November 6, 2026, up 5.8% from the previous close, on volume of 33,542 shares (30-day average 89,801).
Data as of November 6, 2026.
No headlines found.
IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference
Globe Newswire (Thu, 15-Oct 8:00 AM ET)
IRulya Therapeutics Inc is committed to transforming the lives of patients with serious, underserved diseases by developing disease-modifying therapies. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post-lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed; a Phase 2 clinical study in BOS patients is ongoing; a Phase 2b clinical study in PH-ILD is ongoing; and a Phase 2 clinical study in SAPH is ongoing.
Irulya Therapeutics trades on the NASDAQ stock market under the symbol IRLA.
As of November 6, 2026, IRLA stock price climbed to $31.00 with 33,542 million shares trading.
IRLA has a market cap of $31.53 million. This is considered a Sub-Micro Cap stock.
IRLA support price is $26.28 and resistance is $32.34 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IRLA shares will trade within this expected range on the day.
